Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2015
The purpose of this study is to evaluate the efficacy and safety of namilumab in combination with existing methotrexate (MTX) therapy over 24 weeks in participants with moderate to severe early rheumatoid arthritis (RA), diagnosed within 6 months and inadequately controlled by MTX alone.
Epistemonikos ID: 6bc5e0438b8a924d4fca0f00513b389ac7d7a32c
First added on: Mar 23, 2022